NEW YORK, April 21, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Moments ago, Analysts Review released new research updates concerning several important developing situations including Biostar Pharmaceuticals Inc. (NASDAQ: BSPM), China Gerui Adv Mtals Grp Ltd (NASDAQ: CHOP), AirMedia Group Inc. (NASDAQ: AMCN), Panera Bread Company (NASDAQ: PNRA), and Amedica Corporation (NASDAQ: AMDA). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA(R) research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

BSPM Research Report: ( http://get.analystsreview.com/pdf/?c=Biostar%20Pharmaceuticals&d=21-Apr-2015&s=BSPM ),

CHOP Research Report: ( http://get.analystsreview.com/pdf/?c=China%20Gerui&d=21-Apr-2015&s=CHOP ),

AMCN Research Report: ( http://get.analystsreview.com/pdf/?c=AirMedia%20Group&d=21-Apr-2015&s=AMCN ),

PNRA Research Report: ( http://get.analystsreview.com/pdf/?c=Panera%20Bread&d=21-Apr-2015&s=PNRA ),

AMDA Research Report: ( http://get.analystsreview.com/pdf/?c=Amedica%20Corporation&d=21-Apr-2015&s=AMDA ).

============

--

Analyst Update: Financial Results, Corporate Updates,Share Transfer Agreements,and Progress on Initiatives

Reviewed by: Rohit Tuli, CFA(R)

U.S. stocks rallied on Monday, triggered by some good first-quarter earnings reports. The NASDAQ gained 1.27% or 62.79 points, to finish at 4,994.60; the Dow Jones Industrial Average advanced 1.17%, or 208.63 points to 18,034.93, and the S&P 500 ended the session at 2,100.40, up 0.92% or 19.22 points. The gains were broad based as all the sectors closed the session in positive. European stocks too edged higher on Monday, as aggressive easing policy in China offsets the impact of Greece turmoil. Major European markets ended the session higher, as Germany's DAX rose 1.74%; France's CAC advanced 0.86%, and Britain's FTSE 100 jumped 0.82%. Meanwhile, Asian markets mostly disappointed on Monday, amid rising concern over slowdown in the Chinese economy. The Shanghai Composite and Japan's Nikkei both closed lower.

Biostar Pharmaceuticals Inc. (Biostar) announced its Q4 2014 and full year financial results on April 15, 2015. For Q4 net sales stood at $14.4 million up 31.0% YoY, while for the full year 2014, sales rose to $61.4 million. Net income for 2014 was $4.8 million with diluted EPS of $0.33 compared with $0.81 million or diluted EPS of $0.07 in 2013.

China Gerui Adv Mtals Grp Ltd (China Gerui), leading high- precision, cold-rolled steel producer in China announced that on March 4, 2015, it has received a written notice (the "Notice") from the Listing Qualifications department of The Nasdaq Stock Market ("Nasdaq") indicating that the Company is not in compliance with the minimum bid price requirement of $1.00 per share set forth in Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Select Market.

AirMedia Group Inc. (AirMedia), in a press release on April 7, 2015, announced that Beijing Shengshi Lianhe Advertising, a variable interest entity in China, which it currently controls through contractual arrangements (the "VIE structure"), has entered into a share transfer agreement to sell 5% equity interest of AirMedia Group Co., Ltd ("AM Advertising") to Shenzhen Liantronics, for RMB 150 million.

Panera Bread Company (Panera) in a press release dated April 15, 2015, announced progress on a number of key value enhancing initiatives. Firstly, its Board of Directors have approved an increase in the Company's current share repurchase program to $750 million. The Company expects to purchase $500 million of shares within the next twelve months, through a combination of cash on hand, cash flow from operations, and $500 million of new debt.

Amedica Corporation (Amedica), that develops and commercializes silicon nitride ceramics, announced its financial results for the fourth quarter and full year ended December 31, 2014. Total product revenue was reported at $22.8 million for the year 2104, up 2.0% YoY, mainly due to 41% YoY increase in silicon nitride ceramic product revenue.

--

About Analysts Review

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA(R). An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Analysts Review